Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Belgium
  4. Euronext Bruxelles
  5. Hyloris Pharmaceuticals SA
  6. News
  7. All News
    HYL   BE0974363955

HYLORIS PHARMACEUTICALS SA

(HYL)
  Report
Real-time Euronext Bruxelles  -  11:35 2022-09-23 am EDT
12.80 EUR   -5.19%
09/06Pleco Therapeutics B.V. announced that it has received €4.6 million in funding from Hyloris Pharmaceuticals SA, Oost NL BV
CI
09/06Pleco Therapeutics B.V. announced that it has received funding from Oost NL BV, Hyloris Pharmaceuticals SA
CI
09/01Hyloris Pharmaceuticals Reports 2022 Half-Year Results and Provides Corporate Update
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
All news about HYLORIS PHARMACEUTICALS SA
09/06Pleco Therapeutics B.V. announced that it has received €4.6 million in funding fro..
CI
09/06Pleco Therapeutics B.V. announced that it has received funding from Oost NL BV, Hyloris..
CI
09/01Hyloris Pharmaceuticals Reports 2022 Half-Year Results and Provides Corporate Update
GL
09/01Hyloris Pharmaceuticals Reports 2022 Half-Year Results and Provides Corporate Update
GL
08/31HYLORIS PHARMACEUTICALS : 2022 Half-year KPMG Report
PU
08/31HYLORIS PHARMACEUTICALS : 2022 Half-year Report
PU
07/20Hyloris' Oral Mouth Rinse Shows Controlled Bleeding After Tooth Extraction in Early-sta..
MT
07/20Hyloris Reports Positive Phase 1 Data for HY-004, a proprietary Tranexamic Acid Oral Mo..
GL
07/20Hyloris Reports Positive Phase 1 Data for HY-004, a proprietary Tranexamic Acid Oral Mo..
AQ
07/20Hyloris Reports Positive Phase 1 Data for HY-004, A Proprietary Tranexamic Acid Oral Mo..
CI
07/01Hyloris Provides Additional Information on U.S. FDA Review of NDA Application for the R..
GL
07/01Hyloris Provides Additional Information on U.S. FDA Review of NDA Application for the R..
AQ
07/01Hyloris Pharmaceuticals Receives US FDA Request For Additional Information On Maxigesic
MT
07/01US FDA seeks more information on Maxigesic IV® application
GL
07/01Hyloris Pharmaceuticals SA Receives Complete Response Letter from the US Food and Drug ..
CI
07/01HYLORIS PHARMACEUTICALS : Maxigesic - Update
PU
06/26Certain Shares of Hyloris Pharmaceuticals SA are subject to a Lock-Up Agreement Ending ..
CI
04/01Hyloris Successfully Raises EUR 15.0 Million in an Equity Offering by Means of A Privat..
AQ
03/31UPDATE – Hyloris Launches Equity Offering by Means of a Private Placement Via an ..
GL
03/31Hyloris To Start Equity Offering To Raise $17 Million
MT
03/16Correcting -- Hyloris reports results for the full year 2021
GL
03/16Hyloris reports results for the full year 2021
GL
03/16Hyloris Pharmaceuticals SA Reports Earnings Results for the Full Year Ended December 31..
CI
2021Hyloris Partners With Vaneltix Pharma to Develop, Commercialize Interstitial Cystitis P..
MT
2021Hyloris Enters into Strategic Partnership with Vaneltix for Treatment of Acute Pain in ..
AQ
2021Hyloris Enters into Strategic Partnership with Vaneltix for Treatment of Acute Pain in ..
CI
2021US FDA to Decide on Approval of Hyloris Painkiller Earlier Than Expected
MT
2021Hyloris Announces Earlier than Expected PDUFA Date for Maxigesic® IV
GL
2021Hyloris Announces Earlier than Expected PDUFA Date for Maxigesic? IV
CI
2021Hyloris Starts Strategic Partnership With Pleco Therapeutics
MT
2021Hyloris Broadens Pipeline with Novel Patented Combination Product Candidate in Acute My..
AQ
2021Hyloris Broadens Pipeline with Novel Patented Combination Product Candidate in Acute My..
CI
2021Pleco Therapeutics B.V. announced that it expects to receive €1 million in funding..
CI
2021Hyloris Pharmaceuticals Kicks Off Mid-Stage Trial of Vulvovaginal Candidiasis Treatment
MT
2021Hyloris Announces Start of Phase 2 Study of Miconazole-Domiphen Bromide Vaginal Cream i..
AQ
2021Hyloris Pharmaceuticals SA Announces Start of Phase 2 Study of Miconazole-Domiphen Brom..
CI
2021Hyloris Post-Operative Pain Treatment's New Drug Application Gets US FDA Acceptance
MT
2021Hyloris Announces FDA Acceptance of New Drug Application for Maxigesic® IV in Post-Oper..
GL
2021Hyloris Pharmaceuticals SA Announces FDA Acceptance of New Drug Application for Maxiges..
CI
2021HYLORIS PHARMACEUTICALS' : Post-Operative Pain Treatment Gets Regulatory Approvals in UK, ..
MT
2021HYLORIS PHARMACEUTICALS : Announces Approval of Maxigesic® IV in the UK and Ireland
AQ
2021Hyloris Announces Approval of Maxigesic® IV in the UK and Ireland
CI
2021HYLORIS PHARMACEUTICALS : Secures Licensing Deal for Rhoshan's Intravenous Acetylsalicylic..
MT
2021HYLORIS PHARMACEUTICALS : Acquires Breakthrough, Patented Technology to Develop and Market..
AQ
2021Hyloris Pharmaceuticals SA Enters into an Exclusive, Worldwide Licensing Agreement with..
CI
2021HYLORIS PHARMACEUTICALS : Acquires Global Rights to Heart Failure Drug
MT
2021HYLORIS PHARMACEUTICALS : Expands Cardiovascular Pipeline with Breakthrough Extended-Relea..
AQ
2021Hyloris Expands Cardiovascular Pipeline with Breakthrough Extended-Release Milrinone Ca..
CI
2021Hyloris Pharmaceuticals SA acquired Global Rights to CRD-102 from Baker Heart and Diabe..
CI
2021HYLORIS PHARMACEUTICALS : Appoints New CFO From Bone Therapeutics
MT
2021HYLORIS PHARMACEUTICALS : Appoints Jean-Luc Vandebroek as Chief Financial Officer
AQ
2021Hyloris Pharmaceuticals SA Appoints Jean-Luc Vandebroek as its Chief Financial Officer
CI
2021HYLORIS PHARMACEUTICALS' : Post-Operative Pain Drug Wins OK in South Korea, Panama
MT
2021HYLORIS PHARMACEUTICALS : Announces Further Extension of Maxigesic® IV Footprint
AQ
2021Hyloris Pharmaceuticals SA Announces Further Extension of Maxigesic® Iv Footprint
CI
2021Hyloris Pharmaceuticals SA Reports Consolidated Earnings Results for the Half Year Ende..
CI
2021Hyloris Pharmaceuticals Sa Reports Earnings Results for the Second Quarter Ended June 3..
CI
2021HYLORIS PHARMACEUTICALS : to Report 2021 Half-Year Results on 4 August 2021
AQ
2021HYLORIS PHARMACEUTICALS : Starts Selling Non-Opioid Painkiller in Germany, Austria
MT
2021Hyloris Pharmaceuticals Sa Launches Maxigesic IV
CI
2021Certain Subscription Rights of Hyloris Pharmaceuticals SA are subject to a Lock-Up Agre..
CI
2021Certain Warrants of Hyloris Pharmaceuticals SA are subject to a Lock-Up Agreement Endin..
CI
2021Hyloris Successfully Renegotiates License Agreements for Lead Products with the Alter P..
CI
2021HYLORIS PHARMACEUTICALS : Extends Maxigesic IV Licensing Deal to 17 Latin American Countri..
MT
2021Hyloris Announces Extension of Footprint of Maxigesic® IV into South America
GL
2021Hyloris Pharmaceuticals SA Announces Major Commercial Partnership in the U.S. for Maxig..
CI
2021Hyloris Pharmaceuticals SA Reports Consolidated Earnings Results for the Year Ended Dec..
CI
2021Hyloris and Purna Female Healthcare Announce Partnership to Develop Novel Women’s Healt..
CI
2021Purna Female Healthcare announced that it expects to receive €4.3 million in funding fr..
CI
2020Hyloris Pharmaceuticals SA Appoints Dietmar Aichhorn as Chief Operating Officer
CI
2020Hyloris Pharmaceuticals Sa Announces Approval of Maxigesic® IV in Eight European Countr..
CI
2020Hyloris Pharmaceuticals SA Reports Consolidated Earnings Results for the Half Year Ende..
CI
2020Hyloris Pharmaceuticals SA has completed an IPO in the amount of €61.8125 million.
CI
2020Hyloris Pharmaceuticals SA has filed an IPO in the amount of €66.125 million.
CI
2020Hyloris Targets Euronext Brussels Initial Public Offering
CI
1  2Next
Upcoming event on HYLORIS PHARMACEUTICALS SA